Sr Principal Scientist/Principal Scientist at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

PhD with 6+ years of academic / industry research experience in toxicology, or a closely related field
Experience with computational toxicology approaches (e.g., in silico modeling, predictive toxicology, cheminformatics) and/or large-scale data analysis, including machine learning, and ability to translate findings into actionable insights on safety for drug discovery programs
Versed in computational methods, with the ability to identify and evaluate emerging computational trends, and make informed recommendations on their adoption to support early toxicology risk assessment strategies
Ability to generate thorough toxicology target liability assessments for proposed drug discovery targets, including providing suggested approaches and whether proactive follow-up is warranted based on

Responsibilities

Design, execute, interpret and report toxicology studies for evaluating potential toxicity of new drug targets, including new approach methodologies, within drug discovery and communicate these results across multiple disciplines and governance bodies
Perform multifaceted data analysis using specialized software, including analysis of large data sets and/or use of statistical programming to analyze large biological datasets, including transcriptomics and proteomics, for the investigation of mechanisms of toxicity
Apply appropriate models and testing strategies to elucidate mechanisms of toxicity, assess human relevance, and design tools for proactive evaluation and prediction of liabilities associated with new drug entities
Participate in drug discovery teams as a toxicology expert including communication of issues, experimental strategies for resolution and interpretation of results
Discuss and enable transition of drug candidates into the BMS Development organization
Contribute to the collective research expertise in DT including laboratory efforts to advance new tools and innovation in mechanistic toxicology research

Skills

computational toxicology

big data analytics

toxicology

safety assessment

drug metabolism

pharmacokinetics

pharmaceutics

bioanalytical sciences

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free